NASDAQ:BLRX BioLineRx Q3 2024 Earnings Report $3.22 +0.22 (+7.33%) Closing price 04/25/2025 03:56 PM EasternExtended Trading$3.28 +0.06 (+1.86%) As of 04/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast BioLineRx EPS ResultsActual EPS-$2.80Consensus EPS -$3.20Beat/MissBeat by +$0.40One Year Ago EPSN/ABioLineRx Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABioLineRx Announcement DetailsQuarterQ3 2024Date11/25/2024TimeBefore Market OpensConference Call DateMonday, November 25, 2024Conference Call Time8:30AM ETUpcoming EarningsBioLineRx's Q1 2025 earnings is scheduled for Tuesday, May 27, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Earnings HistoryCompany ProfilePowered by BioLineRx Q3 2024 Earnings Call TranscriptProvided by QuartrNovember 25, 2024 ShareLink copied to clipboard.There are 7 speakers on the call. Operator00:00:00Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2024 Financial Results Conference Call. All participants are presently in a listen only mode. Following management's formal presentation, instructions will be given for the question and answer session. I would now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications. Operator00:00:24John, please go ahead. Speaker 100:00:26Thank you, operator. Welcome, everyone. Thank you for joining us on our Q3 2024 results conference call. Earlier today, we issued a press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6 ks. Speaker 100:00:44I'd like to remind you that certain statements we make during the call will be forward looking. Because such statements deal with future risks and are subject to many risks and uncertainties, actual results may differ materially from those in the forward looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20 F and our quarterly reports on Form 6 ks that are filed with the U. S. Securities and Exchange Commission. Speaker 100:01:11At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BylineRx. Speaker 200:01:18Thank you, John, and good morning, everyone, and thank you for joining us on today's call. I'll begin this morning with a recap of the significant licensing agreement that we announced last week with Airmid Limited, followed by a review of our Q3 performance and then Mali Zevi, our Chief Financial Officer, will briefly recap our financials. Afterwards, we will take your questions. Elo Serrani, our Chief Development Officer, is also available for Q and A. Last week, we announced that we executed an exclusive license agreement with EIRMED Limited, the parent company of Gamida Cell Limited for motexa Fortite, which is sold in the U. Speaker 200:01:56S. Under the brand name AFFXTA. Recall that AFFXTA is our FDA approved and commercially available stem cell mobilization agent indicated in combination with G CSF for the collection and subsequent autologous transplantation in patients with multiple myeloma. The agreement covers all indications with the notable exception of solid tumors like pancreatic ductal carcinoma or PDAC and all territories with the exception of Asia where we previously entered into a license agreement with Gloria Biosciences for matixafortide in that region. This transaction is very beneficial for BioLineRx with a $10,000,000 upfront payment, dollars 87,000,000 in potential commercial milestones and very healthy royalties of between 18% 23%. Speaker 200:02:45In addition, we received another $9,000,000 in the form of an equity investment from Highbridge Capital. This aggregate cash influx has enabled the company to finalize an agreement with BlackRock to repay a significant portion of its outstanding debt and restructure the remaining debt on favorable terms. With the transfer of our commercial program to Aramid Gamida Cell, we have also reduced our cash burn in a very substantial manner with our cash runway now extending into 2026. And I will provide more financial details about this shortly. Lastly, the agreement allows us to return to our drug development roots with a streamlined organization that has a proven track record in clinical development and regulatory affairs. Speaker 200:03:30To that end, we will continue to support development of metixoportide in metastatic pancreatic cancer through our existing collaborations, which have the potential to create near term value for shareholders. Over the next year, we also plan to evaluate early stage clinical assets in the areas of oncology and rare disease, where we think we can leverage our expertise in complex drug development and create long term shareholder value. We believe the choice of Gamida Cell as our commercial partner is a fortuitous one. Gamida Cell adds a highly differentiated mobilization agent in Effexa to a commercial portfolio that already includes OmniSurg, the 1st and only FDA approved NAM modified cell therapy for patients with hematologic malignancies in need of an allogeneic hematopoietic cell transplant. We envision Gamida Cell meaningfully growing AFFXTA sales by leveraging its portfolio for improved access to its transplant center customers. Speaker 200:04:30As part of this transaction, Gamida Cell is seeking to transition a significant number of former members of the BioLineRx commercial team who have been so instrumental in the early commercial success of Effexa, driving penetration to over 40% of our target centers and capturing 10% of the market at the end of Q3. In addition, recall that Effexa is also being evaluated in patients with sickle cell disease undergoing gene therapy with 2 Phase 1 investigator initiated trials ongoing, 1 at Washington University in St. Louis and the other at St. Jude Children's Research Hospital. We view this as another opportunity for long term value creation. Speaker 200:05:14Quickly reviewing the terms of the agreement in exchange for the license, we received a 10 a $10,000,000 upfront payment. We also are eligible to receive up to an additional $87,000,000 of potential commercial milestones, plus royalties on net sales of FXA ranging from 18% to 23%. We will also supply matixoportide on a cost plus basis, both for commercial and development supply. In addition, certain funds managed by Hybridge Capital Management have made a $9,000,000 equity investment in BioLineRx. This equity investment and the combined future potential commercial milestones from licensing agreements with Aramid and Loria Biosciences as well as royalties on net sales are expected to provide a strong foundation for our company. Speaker 200:06:01Looking now at the new BioLineRx, concurrent with the partnering transaction, we are shutting down our U. S. Commercial operations. I would like to thank Holly May, who headed our U. S. Speaker 200:06:12Commercial operations for her tireless commitment to building a world class team and ensuring a successful launch. It is largely due to her efforts that we are experiencing strong momentum for AFFXTA, particularly among top tier transplant centers that are leaders with Speaker 300:06:29respect to installing new Speaker 200:06:29therapies on formulary and into effective January 1, 2025 and refocus our efforts on clinical development in Israel. With the proceeds from this transaction, we entered into an agreement with BlackRock to repay $16,500,000 of the approximately 29 $1,000,000 in outstanding debt with the remaining balance restructured at terms very favorable to our company including at the pre existing annual interest rate of 9.5%. With potential revenue from 2 licensing agreements together with a significantly streamlined organization with a greatly reduced cost structure and restructured debt, we are very well positioned to advance our near and long term value creation strategy for investors. At this point, I'd like to review our PDAC program, which we continue to advance through our existing collaborations that require de minimis investment. Recall that motixoportide is an inhibitor of CXCR4, which plays a critical role in establishing and maintaining tumors. Speaker 200:07:44It is highly expressed in over 20 different tumor types and it is estimated that greater than 70% of PDAC patients show an overexpression of CXCR4. PD-one and PD L1 inhibitors have demonstrated significant efficacy significant efficacy in multiple solid tumor types, but no survival benefit in a large randomized PDAC trial comparing combination immunotherapy and standard of care chemotherapy versus standard of care chemotherapy alone. In contrast, a Phase 2 trial in second line patients with metixoportide plus PD-one inhibitor plus standard of care chemotherapy demonstrated improvements across all study endpoints. So while PDAC is an inherently challenging cancer to treat, there is very strong scientific and clinical rationale for continued development. Boticisoportide is being evaluated in an active Phase 2b study led by Columbia University known as chemoformetpanc, which is supported equally by BioLineRx and Regeneron. Speaker 200:08:47Recall that this trial had an initial pilot phase and based on the results of this pilot phase, an assessment would be made on advancing to an expansion phase of the study. 7 of 11 patients in the pilot phase or 64 percent experienced a partial response of which 5 were confirmed PRs as of the July 2023 cut off date with 1 patient experiencing complete resolution of the metastatic lesion in the liver. Along with the 3 patients or 27% experiencing stable disease, this resulted in a disease control rate of 91%. These findings compared favorably to historic partial response and disease control rates of 23% 48%, respectively, reported with the current standard of care. Based on these compelling data, we, along with Columbia and Regeneron, agreed to amend the original expansion phase of the study from a single arm expansion study with a target enrollment of 30 patients to a much larger randomized Phase 2b study of 108 patients with 2 arms. Speaker 200:09:53Metixitfortide, Regeneron's PD-one inhibitor cemiplimab and standard of care chemotherapy versus standard of care chemotherapy alone. The trial's primary endpoint is progression free survival. Secondary objectives include safety, response rate, disease control rate, duration of clinical benefit and overall survival. To further accelerate enrollment, Columbia plans to activate an additional three trial sites over the next two quarters. In addition to the 2 that are currently enrolling, we anticipate that the trial should be fully enrolled by 2027. Speaker 200:10:29Matixifortide is also planned to be evaluated in a planned Phase 2b PDAC study in China led by Gloria Biosciences pursuant to the license agreement that we signed with Gloria in October of last year. That study will evaluate matixifortide in combination with Gloria's commercially approved PD-one inhibitor, zembrolumab and standard of care combination chemotherapy in first line pancreatic cancer. The opportunity for us to help patients in dire need of effective new treatment options, while addressing a multibillion dollar market opportunity is significant. PDAC is a very difficult cancer to treat given that it is often asymptomatic until Stage IV. It has the highest mortality rate among solid tumor malignancies. Speaker 200:11:15Globally, nearly 500,000 people were diagnosed with PDAC in 2020 alone. We look forward to keeping you up to date on our progress in this important program. Now I'd like to briefly review some key performance indicators for Efexda during the Q3, as I believe they reflect the many benefits to transplant centers and patients that key decision makers are increasingly realizing, particularly as they pertain to center efficiency and economics. We've noticed previously, transplant centers, the end users of Phexxa are well defined group in the U. S. Speaker 200:11:50Approximately 80 of the 212 centers in the U. S. Perform roughly 85% of all transplant procedures. Among those 80 centers, by the end of the Q3, we secured formulary placement at institutions managing over 40% of transplant procedures. We also continue to see steady growth in the number of centers reordering product. Speaker 200:12:12Furthermore, we saw an approximate 40% increase in the number of institutions ordering effects during the Q3 as compared to the Q2. As the Q3 was only the 3rd full since launch, we are very pleased with the traction that we've seen, especially with the availability of Plirixa-four or generic mozavil, which entered the market shortly before our launch. In fact, during the 3rd quarter, we achieved a 10% market share milestone of total CXCR4 inhibitor usage in the U. S, which compares Apexta to branded mozavil and generic palerixapore across all indications. We believe that this strong growth trajectory will continue through Gamida Cell's commercial program, building on the strong foundation in place. Speaker 200:12:59As we have discussed on prior conference calls, there are a number of factors that are driving the need for more effective mobilization regimens. 1st, multiple myeloma patients are getting older and these patients are more challenged to achieve their required stem cell yields for transplantation. In addition, the growing use of quad induction Speaker 300:13:18therapies, while beneficial to patients, Speaker 200:13:18can negatively impact stem cell cell yields. Speaker 300:13:22Last quarter, we cited the PERSEUS trial in which Speaker 200:13:22a recent FDA approved quad therapy was shown to reduce risk of disease progression or death in multiple myeloma patients by 60 60%, pointing to the trend toward quad therapies as a new standard of care induction therapy. It is against this backdrop of a rapidly changing stem cell mobilization treatment landscape that we believe AVEXTA can address significant unmet needs in the market. We are pleased to have entrusted its future success to an ideal partner like Gamida Cell with the expertise and infrastructure to maximize AVEXTA's commercial potential. Now let me turn the call over to Mollie to provide a financial update. Mollie, please go ahead. Speaker 400:14:08Thank you, Phil. As is our practice, I will go over the most significant items in our financial statements, revenues, cost of revenues, research and development expenses, sales and marketing expenses, net loss and cash. I invite you to review the 6 ks filing we made this morning that contains our financials and press release. Total revenue for the 3 months ended September 30, 2024 was $4,900,000 The company did not record any revenue during the Q3 of 2023. Revenue for the quarter reflects a portion of the upfront payment from the Gloria Biosciences license, which amounted to $3,200,000 as well as $1,700,000 for the net revenue from product sales of Speaker 300:15:00FXTA in the U. S. Cost of Speaker 400:15:00revenue for the 3 months ended September 30, 2024 was $800,000 The company did not record any cost of revenue during the Q3 of 2023. Cost of revenue for the quarter primarily reflects the amortization of intangible assets, royalties on net product sales of FXA in the U. S. And cost of goods sold on product sales. Research and development expenses for the 3 months ended September 30, 2024 were $2,600,000 compared to $2,700,000 for the same period in 2023. Speaker 400:15:41The decrease resulted primarily from lower expenses related to the termination of the development of AGI-one hundred and thirty four and a decrease in payroll and share based compensation. Sales and marketing expenses for the 3 months ended September 30, 2024 were $5,500,000 compared to $8,100,000 for the same period in 2023. The decrease resulted primarily from lower expenses of commercialization activities related to Motixa Forti. The higher expenses in the corresponding period of 2023 reflect the ramp up of pre commercialization activities related to Motixa Forti. General and administrative expenses for the 3 months ended September 30, 2024 were $1,400,000 compared to $1,500,000 for the same period in 2023. Speaker 400:16:38The decrease resulted primarily from small decreases in a number of G and A items. Net loss for the 3 months ended September 30, 2024 was $5,800,000 compared to net loss of $16,000,000 for the same period in 2023. The net loss for the 2024 period included $800,000 in non operating income compared to non operating expenses of $3,100,000 for the same period in 2023, both primarily related to non cash reevaluation of warrants. As of September 30, 2024, the company had cash, cash equivalents and short term bank deposits of $29,200,000 Following the out license to Airmid, the equity investment from Highbridge and the debt repayment to BlackRock, the company's cash, cash equivalents and short term bank deposits are expected to be approximately $20,000,000 which we believe will be sufficient to fund operations into 2026 as currently planned. And with that, I'll turn the call over to Phil. Speaker 200:17:52Thank you, Molly. In closing, I would like to take a moment to summarize our revised milestones. Over the next two quarters, we anticipate adding 3 new clinical trial sites to the ongoing chemo for medpeng Phase 2b randomized clinical trial in first line PDAC sponsored by Columbia University and anticipate interim data in 2026. Working with Gloria Bio, we look forward to continued progress with planned stem cell mobilization bridging study and the Phase 2b combination study evaluating matixifortide in first line pancreatic cancer. Finally, in 2025, we will evaluate additional early stage clinical assets for in licensing the development, seeking to add 1 new asset in 2025 and an additional one in 2026. Speaker 200:18:39With that, we have now concluded the formal part of our presentation. Operator, we will now open the call to questions. Operator00:18:46Thank you. Ladies and gentlemen, at this time, we will begin the question and answer session. The first question is from Joe Pantginis of H. C. Wainwright. Operator00:19:12Please go ahead. Speaker 500:19:15Hey, everybody. Got a few questions, if you don't mind. So first, Phil, I just wanted to make sure I heard you correctly with regard to pipeline growth. Did you say potential in lysing of 1 asset in 2025 and 1 in 2026? Speaker 200:19:29Yes, I think that's what our plan is. We have a number of assets that we're already looking at. It's hard to say BD things don't always go exactly according to plan, but I think overall that's our plan. Speaker 500:19:41Of course, okay. So then going to your current announcements and thank you for all the details today that Speaker 100:19:47were very Speaker 500:19:47helpful. With regard to say the pancreatic program, I guess how do we mix that with the potential for matixifortide in additional solid tumor indications plus the ability to potentially have a business development discussions around that and can you discuss the level of maturity of these discussions? Speaker 200:20:12Yes. So as far as the PDAC, I think that we look at PDAC as sort of as a prototype, so to speak, for other solid tumors. We are probably not going to put a lot more money at this point into PDAC. As you know, we have the 2 collaborations that are ongoing that are really running in the background with at a very low cost to the company, basically drug the supply of drug product. And so we think the best use for our current capital is to bring some new assets into the pipeline while these programs are still ongoing. Speaker 200:20:49And we hope that there will be some initial data sometime next year in I'm sorry, next in 2026, some interim data from the Columbia study, which then would serve as probably the launching off point for some potential business development discussions, etcetera. Speaker 500:21:09That's very helpful. And then with regards to the Amyrid, affects the sale, couple of things here. So just from a logistical standpoint, do they have any potential option on the solid tumor program? They do not. They do not. Speaker 500:21:24Okay, that's simple enough. And I guess two things here. So with regard to the company restructuring, it sounds like that it's mostly or largely the field force that they'll be assimilating? Speaker 200:21:38Not necessarily. I mean, I don't think we're going to liberty to tell you to speak for them, but they have they are taking a piece of our organization or a number of our personnel and I don't think it's only limited to field to customer facing Speaker 500:21:57employees. Okay. And then my last question is, I guess from a financial standpoint and the important details you shared with regard to the drug launch to date, how should we sort of view to the level of detail you can sort of the integration time within their program of AFFXTA and how that might impact any potential lags or dips in sales, especially as we go into the Q1 and insurance resets, etcetera? Speaker 200:22:27Yes. So I'm hoping that there won't be too much of a lag in anything. They're taking, like I said, a significant number of employees with them. We're also, according to the agreement, we're providing them with transition services for the next number of months. And so we think we're going to ASH. Speaker 200:22:49We're probably going to Tandem as well. So I think that we believe that the transition period should be quite seamless. And I don't believe there'll be a significant lag in sales or in the uptick of sales. Speaker 500:23:07Thank you very much. Speaker 200:23:08All right, Joe. Have a great day. Operator00:23:11The next question is from Justin Walsh of Jones Trading. Please go ahead. Speaker 100:23:19Hi, thanks for taking the question. I wonder if you can provide some color on where you view the company's core competencies as we wait to hear more about the addition of potential assets to your pipeline? Speaker 200:23:31Thanks, Justin. Good morning. So I mean, as we mentioned, we'll be returning to our roots as an Israeli based development company. But with many I think we have many positive attributes that other companies may not have. We have a highly experienced development team with fully validated capabilities from early stage projects all the way to approval and of course commercialization, but I'll just talk about it until approval. Speaker 200:24:02So those are some of our capabilities. We have a full our Israeli team has full capabilities in regulatory affairs in CMC, in quality assurance, in clinical operations, in preclinical development, etcetera. So I mean, we've got in medical affairs and etcetera. So we've got a full complement of the disciplines necessary to move forward in development. I think just to even to go further with that, I think that we also have cash flows from 2 partnering arrangements that will provide commercial milestones and royalty revenues on an ongoing basis that other development companies might have. Speaker 200:24:49And we also have, as I mentioned, we have the significant trials in PDAC that are ongoing under these meaningful collaborations that are really moving forward at a de minimis cost to the company. So I think all in all, I think that we feel that we're very well placed moving forward. And again, as I mentioned, we're looking to bring in 2 new assets in the 2025, 2025, 2026 period. We have a list of potential and licensed candidates. All of them sort of meet our criteria of a low upfront payment in oncology and rare disease with relatively modest and affordable clinical development programs. Speaker 200:25:30So I mean that's sort of how we see ourselves moving forward. I hope that gave you a comprehensive answer to your question. Speaker 100:25:38Yes, definitely. Thanks for taking the question. Speaker 200:25:41Great. Operator00:25:44The next question is from John von der Mostyn of Zacks. Please go ahead. Speaker 600:25:52Thank you and hello Phil and Molly. Looking at the 2025 expenses, I think you indicated there'd be a 70% reduction in spend next year. And I guess, if we look at kind of the estimates out there, it seems like we just take out sales and marketing expense and leave R and D and G and A kind of as they have been. Is that a fair way to look at it? And also, obviously, take out the cost of goods sold as well? Speaker 600:26:20I think it's going to be Speaker 200:26:21a little bit more than that. I think we're going to as a company that also had operations in the U. S, besides the actual U. S. Commercial operations, I think that some of our spend from Israel having a U. Speaker 200:26:35S. Subsidiary that was active created some additional spend. So I think it's a little bit more than that. I think you can expect a decrease in G and A expenses as well and etcetera. So we're looking to be lean and mean going forward. Speaker 200:26:52And as I said, we believe that we will be on the right track with moving forward with development only in Israel. Again, I think I also want to mention that Israel itself is sort of a low cost place to have development. And so I think that we are looking at that over 70% reduction overall in spend. Speaker 600:27:18Okay. And then on the R and D side, should we think of that kind of continuing on at the same level? And what are those obligations going to be? I mean, I think there's PDAC in there. Is there anything else in there that's ongoing? Speaker 200:27:31Yes. So we are we have some obligations regarding some 5 year commitment post marketing commitment with the FDA, but that's not very significant. And as well, our PDAC commitments Speaker 300:27:49are Speaker 200:27:49more our drug supply plus some small grant, nothing significant. So, I mean, we're going to be having PDECs, 2 Phase 2b studies hopefully ongoing at almost no cost to the company. The post marketing commitment will be quite low. And then the rest of our spend will be on new projects as we bring them in. Speaker 600:28:15Okay. And as we look at potentially a pivotal or registrational trial in PDAC, I guess you seem to indicate that that would be taken over by partners and that you would probably have limited contribution there? Yes. I mean, listen, I contribution there? Speaker 200:28:28Yes. I mean, listen, everything is possible, but I think we believe that something of this size in solid tumors in general, it would make sense to partner, especially if we have very robust data from the Phase 2b or from the Phase 2bs. So I think our probably our main pathway forward would be to look to partner it out. And this being such a blockbuster indication, we don't really think that it would be difficult depending, of course, on the data. Okay. Speaker 600:29:13So that seems to orient your attention more towards earlier stage products. So I guess, how would you think about adding a new product? I mean, what stage of development would it be in? I think oncology probably is an area where you have some experience. How would you time to commercialization, stage develop and indication, what are those kind of factors that you're thinking about when you're looking at something to layer on? Speaker 600:29:41Yes. So I mean, I said, Speaker 200:29:42I think we're looking at oncology rare disease. We're looking at early stage clinical assets. I can't say that that's the only thing that we'd look at, maybe something very, very late stage preclinical, but I think our focus is primarily on early stage clinical assets with best in class potential and with small molecules, peptides, things that we have a lot of experience with previously and to sort of leverage our capabilities going forward. Speaker 600:30:21Okay. And then on China, it seemed like you had mentioned that there's clearance there, I guess, in some areas that don't require the bridging study. When would you expect the first revenues to show up from that region? Speaker 200:30:35That's hard to say. I mean, it could it's hard for us to say right now. I mean, we haven't given any guidance on that. We're hoping that 2025 will be a year where there is revenues, although we don't have a lot of control over what's going up what Glory is doing, we're obviously meeting with them on a regular basis. I would imagine that that first sale should occur sometime in 2025. Operator00:31:21A follow-up question from John Van der Mosten of Zacks. Please go ahead. Speaker 600:31:27Great. Thanks for one more. On Gamida Cell, are they is the only other product that they're commercializing the Omnisurge product or do they have something else besides that currently? Speaker 200:31:38Right now, that's what they have. I think they may have plans to bring in some additional products, but right now they have OmniSurg and of course now they have AVEXTA. Speaker 600:31:49Great. All right. Thank you. Operator00:31:53There are no further questions at this time. Before I ask Mr. Phil Serlin to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin 2 hours after the conference. In the U. S, please call 1888-295-2634. Operator00:32:12In Israel, please call 3,9,250,904. Internationally, please call 9723,9,250,9 4. Mr. Serlin, would you like to make your concluding statement? Speaker 200:32:25Yes. Thank you, operator. In closing, we are very pleased to have entered into this licensing agreement with Aramid Gamida Cell, which allows us to return to our drug development roots while simultaneously benefiting from FX's long term commercial potentials in stem cell mobilization, sickle cell disease and other non solid tumor indications. We believe this path forward best positions us to create value for our shareholders while developing novel new therapies for patients with cancer and serious rare diseases. Thank you all very much for your continued interest in BioLineRx. Speaker 200:33:02We look forward to providing our next comprehensive quarterly update in March. Be safe and have a great day. Operator00:33:08Thank you. This concludes the BioLineRx Third Quarter 2024 Conference Call. Thank you for your participation. You may go ahead and disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallBioLineRx Q3 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K) BioLineRx Earnings HeadlinesBioLineRx stock rating cut to Hold at Jones TradingApril 3, 2025 | investing.comBLRX: 2024 Financial ResultsApril 3, 2025 | finance.yahoo.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 27, 2025 | American Alternative (Ad)BioLineRx downgraded to Hold from Buy at JonesResearchApril 2, 2025 | markets.businessinsider.comBioLineRx Ltd. (NASDAQ:BLRX) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comBioLineRx price target adjusted to $26 at H.C. Wainwright after reverse splitApril 1, 2025 | markets.businessinsider.comSee More BioLineRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioLineRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLineRx and other key companies, straight to your email. Email Address About BioLineRxBioLineRx (NASDAQ:BLRX), a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.View BioLineRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 7 speakers on the call. Operator00:00:00Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2024 Financial Results Conference Call. All participants are presently in a listen only mode. Following management's formal presentation, instructions will be given for the question and answer session. I would now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications. Operator00:00:24John, please go ahead. Speaker 100:00:26Thank you, operator. Welcome, everyone. Thank you for joining us on our Q3 2024 results conference call. Earlier today, we issued a press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6 ks. Speaker 100:00:44I'd like to remind you that certain statements we make during the call will be forward looking. Because such statements deal with future risks and are subject to many risks and uncertainties, actual results may differ materially from those in the forward looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20 F and our quarterly reports on Form 6 ks that are filed with the U. S. Securities and Exchange Commission. Speaker 100:01:11At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BylineRx. Speaker 200:01:18Thank you, John, and good morning, everyone, and thank you for joining us on today's call. I'll begin this morning with a recap of the significant licensing agreement that we announced last week with Airmid Limited, followed by a review of our Q3 performance and then Mali Zevi, our Chief Financial Officer, will briefly recap our financials. Afterwards, we will take your questions. Elo Serrani, our Chief Development Officer, is also available for Q and A. Last week, we announced that we executed an exclusive license agreement with EIRMED Limited, the parent company of Gamida Cell Limited for motexa Fortite, which is sold in the U. Speaker 200:01:56S. Under the brand name AFFXTA. Recall that AFFXTA is our FDA approved and commercially available stem cell mobilization agent indicated in combination with G CSF for the collection and subsequent autologous transplantation in patients with multiple myeloma. The agreement covers all indications with the notable exception of solid tumors like pancreatic ductal carcinoma or PDAC and all territories with the exception of Asia where we previously entered into a license agreement with Gloria Biosciences for matixafortide in that region. This transaction is very beneficial for BioLineRx with a $10,000,000 upfront payment, dollars 87,000,000 in potential commercial milestones and very healthy royalties of between 18% 23%. Speaker 200:02:45In addition, we received another $9,000,000 in the form of an equity investment from Highbridge Capital. This aggregate cash influx has enabled the company to finalize an agreement with BlackRock to repay a significant portion of its outstanding debt and restructure the remaining debt on favorable terms. With the transfer of our commercial program to Aramid Gamida Cell, we have also reduced our cash burn in a very substantial manner with our cash runway now extending into 2026. And I will provide more financial details about this shortly. Lastly, the agreement allows us to return to our drug development roots with a streamlined organization that has a proven track record in clinical development and regulatory affairs. Speaker 200:03:30To that end, we will continue to support development of metixoportide in metastatic pancreatic cancer through our existing collaborations, which have the potential to create near term value for shareholders. Over the next year, we also plan to evaluate early stage clinical assets in the areas of oncology and rare disease, where we think we can leverage our expertise in complex drug development and create long term shareholder value. We believe the choice of Gamida Cell as our commercial partner is a fortuitous one. Gamida Cell adds a highly differentiated mobilization agent in Effexa to a commercial portfolio that already includes OmniSurg, the 1st and only FDA approved NAM modified cell therapy for patients with hematologic malignancies in need of an allogeneic hematopoietic cell transplant. We envision Gamida Cell meaningfully growing AFFXTA sales by leveraging its portfolio for improved access to its transplant center customers. Speaker 200:04:30As part of this transaction, Gamida Cell is seeking to transition a significant number of former members of the BioLineRx commercial team who have been so instrumental in the early commercial success of Effexa, driving penetration to over 40% of our target centers and capturing 10% of the market at the end of Q3. In addition, recall that Effexa is also being evaluated in patients with sickle cell disease undergoing gene therapy with 2 Phase 1 investigator initiated trials ongoing, 1 at Washington University in St. Louis and the other at St. Jude Children's Research Hospital. We view this as another opportunity for long term value creation. Speaker 200:05:14Quickly reviewing the terms of the agreement in exchange for the license, we received a 10 a $10,000,000 upfront payment. We also are eligible to receive up to an additional $87,000,000 of potential commercial milestones, plus royalties on net sales of FXA ranging from 18% to 23%. We will also supply matixoportide on a cost plus basis, both for commercial and development supply. In addition, certain funds managed by Hybridge Capital Management have made a $9,000,000 equity investment in BioLineRx. This equity investment and the combined future potential commercial milestones from licensing agreements with Aramid and Loria Biosciences as well as royalties on net sales are expected to provide a strong foundation for our company. Speaker 200:06:01Looking now at the new BioLineRx, concurrent with the partnering transaction, we are shutting down our U. S. Commercial operations. I would like to thank Holly May, who headed our U. S. Speaker 200:06:12Commercial operations for her tireless commitment to building a world class team and ensuring a successful launch. It is largely due to her efforts that we are experiencing strong momentum for AFFXTA, particularly among top tier transplant centers that are leaders with Speaker 300:06:29respect to installing new Speaker 200:06:29therapies on formulary and into effective January 1, 2025 and refocus our efforts on clinical development in Israel. With the proceeds from this transaction, we entered into an agreement with BlackRock to repay $16,500,000 of the approximately 29 $1,000,000 in outstanding debt with the remaining balance restructured at terms very favorable to our company including at the pre existing annual interest rate of 9.5%. With potential revenue from 2 licensing agreements together with a significantly streamlined organization with a greatly reduced cost structure and restructured debt, we are very well positioned to advance our near and long term value creation strategy for investors. At this point, I'd like to review our PDAC program, which we continue to advance through our existing collaborations that require de minimis investment. Recall that motixoportide is an inhibitor of CXCR4, which plays a critical role in establishing and maintaining tumors. Speaker 200:07:44It is highly expressed in over 20 different tumor types and it is estimated that greater than 70% of PDAC patients show an overexpression of CXCR4. PD-one and PD L1 inhibitors have demonstrated significant efficacy significant efficacy in multiple solid tumor types, but no survival benefit in a large randomized PDAC trial comparing combination immunotherapy and standard of care chemotherapy versus standard of care chemotherapy alone. In contrast, a Phase 2 trial in second line patients with metixoportide plus PD-one inhibitor plus standard of care chemotherapy demonstrated improvements across all study endpoints. So while PDAC is an inherently challenging cancer to treat, there is very strong scientific and clinical rationale for continued development. Boticisoportide is being evaluated in an active Phase 2b study led by Columbia University known as chemoformetpanc, which is supported equally by BioLineRx and Regeneron. Speaker 200:08:47Recall that this trial had an initial pilot phase and based on the results of this pilot phase, an assessment would be made on advancing to an expansion phase of the study. 7 of 11 patients in the pilot phase or 64 percent experienced a partial response of which 5 were confirmed PRs as of the July 2023 cut off date with 1 patient experiencing complete resolution of the metastatic lesion in the liver. Along with the 3 patients or 27% experiencing stable disease, this resulted in a disease control rate of 91%. These findings compared favorably to historic partial response and disease control rates of 23% 48%, respectively, reported with the current standard of care. Based on these compelling data, we, along with Columbia and Regeneron, agreed to amend the original expansion phase of the study from a single arm expansion study with a target enrollment of 30 patients to a much larger randomized Phase 2b study of 108 patients with 2 arms. Speaker 200:09:53Metixitfortide, Regeneron's PD-one inhibitor cemiplimab and standard of care chemotherapy versus standard of care chemotherapy alone. The trial's primary endpoint is progression free survival. Secondary objectives include safety, response rate, disease control rate, duration of clinical benefit and overall survival. To further accelerate enrollment, Columbia plans to activate an additional three trial sites over the next two quarters. In addition to the 2 that are currently enrolling, we anticipate that the trial should be fully enrolled by 2027. Speaker 200:10:29Matixifortide is also planned to be evaluated in a planned Phase 2b PDAC study in China led by Gloria Biosciences pursuant to the license agreement that we signed with Gloria in October of last year. That study will evaluate matixifortide in combination with Gloria's commercially approved PD-one inhibitor, zembrolumab and standard of care combination chemotherapy in first line pancreatic cancer. The opportunity for us to help patients in dire need of effective new treatment options, while addressing a multibillion dollar market opportunity is significant. PDAC is a very difficult cancer to treat given that it is often asymptomatic until Stage IV. It has the highest mortality rate among solid tumor malignancies. Speaker 200:11:15Globally, nearly 500,000 people were diagnosed with PDAC in 2020 alone. We look forward to keeping you up to date on our progress in this important program. Now I'd like to briefly review some key performance indicators for Efexda during the Q3, as I believe they reflect the many benefits to transplant centers and patients that key decision makers are increasingly realizing, particularly as they pertain to center efficiency and economics. We've noticed previously, transplant centers, the end users of Phexxa are well defined group in the U. S. Speaker 200:11:50Approximately 80 of the 212 centers in the U. S. Perform roughly 85% of all transplant procedures. Among those 80 centers, by the end of the Q3, we secured formulary placement at institutions managing over 40% of transplant procedures. We also continue to see steady growth in the number of centers reordering product. Speaker 200:12:12Furthermore, we saw an approximate 40% increase in the number of institutions ordering effects during the Q3 as compared to the Q2. As the Q3 was only the 3rd full since launch, we are very pleased with the traction that we've seen, especially with the availability of Plirixa-four or generic mozavil, which entered the market shortly before our launch. In fact, during the 3rd quarter, we achieved a 10% market share milestone of total CXCR4 inhibitor usage in the U. S, which compares Apexta to branded mozavil and generic palerixapore across all indications. We believe that this strong growth trajectory will continue through Gamida Cell's commercial program, building on the strong foundation in place. Speaker 200:12:59As we have discussed on prior conference calls, there are a number of factors that are driving the need for more effective mobilization regimens. 1st, multiple myeloma patients are getting older and these patients are more challenged to achieve their required stem cell yields for transplantation. In addition, the growing use of quad induction Speaker 300:13:18therapies, while beneficial to patients, Speaker 200:13:18can negatively impact stem cell cell yields. Speaker 300:13:22Last quarter, we cited the PERSEUS trial in which Speaker 200:13:22a recent FDA approved quad therapy was shown to reduce risk of disease progression or death in multiple myeloma patients by 60 60%, pointing to the trend toward quad therapies as a new standard of care induction therapy. It is against this backdrop of a rapidly changing stem cell mobilization treatment landscape that we believe AVEXTA can address significant unmet needs in the market. We are pleased to have entrusted its future success to an ideal partner like Gamida Cell with the expertise and infrastructure to maximize AVEXTA's commercial potential. Now let me turn the call over to Mollie to provide a financial update. Mollie, please go ahead. Speaker 400:14:08Thank you, Phil. As is our practice, I will go over the most significant items in our financial statements, revenues, cost of revenues, research and development expenses, sales and marketing expenses, net loss and cash. I invite you to review the 6 ks filing we made this morning that contains our financials and press release. Total revenue for the 3 months ended September 30, 2024 was $4,900,000 The company did not record any revenue during the Q3 of 2023. Revenue for the quarter reflects a portion of the upfront payment from the Gloria Biosciences license, which amounted to $3,200,000 as well as $1,700,000 for the net revenue from product sales of Speaker 300:15:00FXTA in the U. S. Cost of Speaker 400:15:00revenue for the 3 months ended September 30, 2024 was $800,000 The company did not record any cost of revenue during the Q3 of 2023. Cost of revenue for the quarter primarily reflects the amortization of intangible assets, royalties on net product sales of FXA in the U. S. And cost of goods sold on product sales. Research and development expenses for the 3 months ended September 30, 2024 were $2,600,000 compared to $2,700,000 for the same period in 2023. Speaker 400:15:41The decrease resulted primarily from lower expenses related to the termination of the development of AGI-one hundred and thirty four and a decrease in payroll and share based compensation. Sales and marketing expenses for the 3 months ended September 30, 2024 were $5,500,000 compared to $8,100,000 for the same period in 2023. The decrease resulted primarily from lower expenses of commercialization activities related to Motixa Forti. The higher expenses in the corresponding period of 2023 reflect the ramp up of pre commercialization activities related to Motixa Forti. General and administrative expenses for the 3 months ended September 30, 2024 were $1,400,000 compared to $1,500,000 for the same period in 2023. Speaker 400:16:38The decrease resulted primarily from small decreases in a number of G and A items. Net loss for the 3 months ended September 30, 2024 was $5,800,000 compared to net loss of $16,000,000 for the same period in 2023. The net loss for the 2024 period included $800,000 in non operating income compared to non operating expenses of $3,100,000 for the same period in 2023, both primarily related to non cash reevaluation of warrants. As of September 30, 2024, the company had cash, cash equivalents and short term bank deposits of $29,200,000 Following the out license to Airmid, the equity investment from Highbridge and the debt repayment to BlackRock, the company's cash, cash equivalents and short term bank deposits are expected to be approximately $20,000,000 which we believe will be sufficient to fund operations into 2026 as currently planned. And with that, I'll turn the call over to Phil. Speaker 200:17:52Thank you, Molly. In closing, I would like to take a moment to summarize our revised milestones. Over the next two quarters, we anticipate adding 3 new clinical trial sites to the ongoing chemo for medpeng Phase 2b randomized clinical trial in first line PDAC sponsored by Columbia University and anticipate interim data in 2026. Working with Gloria Bio, we look forward to continued progress with planned stem cell mobilization bridging study and the Phase 2b combination study evaluating matixifortide in first line pancreatic cancer. Finally, in 2025, we will evaluate additional early stage clinical assets for in licensing the development, seeking to add 1 new asset in 2025 and an additional one in 2026. Speaker 200:18:39With that, we have now concluded the formal part of our presentation. Operator, we will now open the call to questions. Operator00:18:46Thank you. Ladies and gentlemen, at this time, we will begin the question and answer session. The first question is from Joe Pantginis of H. C. Wainwright. Operator00:19:12Please go ahead. Speaker 500:19:15Hey, everybody. Got a few questions, if you don't mind. So first, Phil, I just wanted to make sure I heard you correctly with regard to pipeline growth. Did you say potential in lysing of 1 asset in 2025 and 1 in 2026? Speaker 200:19:29Yes, I think that's what our plan is. We have a number of assets that we're already looking at. It's hard to say BD things don't always go exactly according to plan, but I think overall that's our plan. Speaker 500:19:41Of course, okay. So then going to your current announcements and thank you for all the details today that Speaker 100:19:47were very Speaker 500:19:47helpful. With regard to say the pancreatic program, I guess how do we mix that with the potential for matixifortide in additional solid tumor indications plus the ability to potentially have a business development discussions around that and can you discuss the level of maturity of these discussions? Speaker 200:20:12Yes. So as far as the PDAC, I think that we look at PDAC as sort of as a prototype, so to speak, for other solid tumors. We are probably not going to put a lot more money at this point into PDAC. As you know, we have the 2 collaborations that are ongoing that are really running in the background with at a very low cost to the company, basically drug the supply of drug product. And so we think the best use for our current capital is to bring some new assets into the pipeline while these programs are still ongoing. Speaker 200:20:49And we hope that there will be some initial data sometime next year in I'm sorry, next in 2026, some interim data from the Columbia study, which then would serve as probably the launching off point for some potential business development discussions, etcetera. Speaker 500:21:09That's very helpful. And then with regards to the Amyrid, affects the sale, couple of things here. So just from a logistical standpoint, do they have any potential option on the solid tumor program? They do not. They do not. Speaker 500:21:24Okay, that's simple enough. And I guess two things here. So with regard to the company restructuring, it sounds like that it's mostly or largely the field force that they'll be assimilating? Speaker 200:21:38Not necessarily. I mean, I don't think we're going to liberty to tell you to speak for them, but they have they are taking a piece of our organization or a number of our personnel and I don't think it's only limited to field to customer facing Speaker 500:21:57employees. Okay. And then my last question is, I guess from a financial standpoint and the important details you shared with regard to the drug launch to date, how should we sort of view to the level of detail you can sort of the integration time within their program of AFFXTA and how that might impact any potential lags or dips in sales, especially as we go into the Q1 and insurance resets, etcetera? Speaker 200:22:27Yes. So I'm hoping that there won't be too much of a lag in anything. They're taking, like I said, a significant number of employees with them. We're also, according to the agreement, we're providing them with transition services for the next number of months. And so we think we're going to ASH. Speaker 200:22:49We're probably going to Tandem as well. So I think that we believe that the transition period should be quite seamless. And I don't believe there'll be a significant lag in sales or in the uptick of sales. Speaker 500:23:07Thank you very much. Speaker 200:23:08All right, Joe. Have a great day. Operator00:23:11The next question is from Justin Walsh of Jones Trading. Please go ahead. Speaker 100:23:19Hi, thanks for taking the question. I wonder if you can provide some color on where you view the company's core competencies as we wait to hear more about the addition of potential assets to your pipeline? Speaker 200:23:31Thanks, Justin. Good morning. So I mean, as we mentioned, we'll be returning to our roots as an Israeli based development company. But with many I think we have many positive attributes that other companies may not have. We have a highly experienced development team with fully validated capabilities from early stage projects all the way to approval and of course commercialization, but I'll just talk about it until approval. Speaker 200:24:02So those are some of our capabilities. We have a full our Israeli team has full capabilities in regulatory affairs in CMC, in quality assurance, in clinical operations, in preclinical development, etcetera. So I mean, we've got in medical affairs and etcetera. So we've got a full complement of the disciplines necessary to move forward in development. I think just to even to go further with that, I think that we also have cash flows from 2 partnering arrangements that will provide commercial milestones and royalty revenues on an ongoing basis that other development companies might have. Speaker 200:24:49And we also have, as I mentioned, we have the significant trials in PDAC that are ongoing under these meaningful collaborations that are really moving forward at a de minimis cost to the company. So I think all in all, I think that we feel that we're very well placed moving forward. And again, as I mentioned, we're looking to bring in 2 new assets in the 2025, 2025, 2026 period. We have a list of potential and licensed candidates. All of them sort of meet our criteria of a low upfront payment in oncology and rare disease with relatively modest and affordable clinical development programs. Speaker 200:25:30So I mean that's sort of how we see ourselves moving forward. I hope that gave you a comprehensive answer to your question. Speaker 100:25:38Yes, definitely. Thanks for taking the question. Speaker 200:25:41Great. Operator00:25:44The next question is from John von der Mostyn of Zacks. Please go ahead. Speaker 600:25:52Thank you and hello Phil and Molly. Looking at the 2025 expenses, I think you indicated there'd be a 70% reduction in spend next year. And I guess, if we look at kind of the estimates out there, it seems like we just take out sales and marketing expense and leave R and D and G and A kind of as they have been. Is that a fair way to look at it? And also, obviously, take out the cost of goods sold as well? Speaker 600:26:20I think it's going to be Speaker 200:26:21a little bit more than that. I think we're going to as a company that also had operations in the U. S, besides the actual U. S. Commercial operations, I think that some of our spend from Israel having a U. Speaker 200:26:35S. Subsidiary that was active created some additional spend. So I think it's a little bit more than that. I think you can expect a decrease in G and A expenses as well and etcetera. So we're looking to be lean and mean going forward. Speaker 200:26:52And as I said, we believe that we will be on the right track with moving forward with development only in Israel. Again, I think I also want to mention that Israel itself is sort of a low cost place to have development. And so I think that we are looking at that over 70% reduction overall in spend. Speaker 600:27:18Okay. And then on the R and D side, should we think of that kind of continuing on at the same level? And what are those obligations going to be? I mean, I think there's PDAC in there. Is there anything else in there that's ongoing? Speaker 200:27:31Yes. So we are we have some obligations regarding some 5 year commitment post marketing commitment with the FDA, but that's not very significant. And as well, our PDAC commitments Speaker 300:27:49are Speaker 200:27:49more our drug supply plus some small grant, nothing significant. So, I mean, we're going to be having PDECs, 2 Phase 2b studies hopefully ongoing at almost no cost to the company. The post marketing commitment will be quite low. And then the rest of our spend will be on new projects as we bring them in. Speaker 600:28:15Okay. And as we look at potentially a pivotal or registrational trial in PDAC, I guess you seem to indicate that that would be taken over by partners and that you would probably have limited contribution there? Yes. I mean, listen, I contribution there? Speaker 200:28:28Yes. I mean, listen, everything is possible, but I think we believe that something of this size in solid tumors in general, it would make sense to partner, especially if we have very robust data from the Phase 2b or from the Phase 2bs. So I think our probably our main pathway forward would be to look to partner it out. And this being such a blockbuster indication, we don't really think that it would be difficult depending, of course, on the data. Okay. Speaker 600:29:13So that seems to orient your attention more towards earlier stage products. So I guess, how would you think about adding a new product? I mean, what stage of development would it be in? I think oncology probably is an area where you have some experience. How would you time to commercialization, stage develop and indication, what are those kind of factors that you're thinking about when you're looking at something to layer on? Speaker 600:29:41Yes. So I mean, I said, Speaker 200:29:42I think we're looking at oncology rare disease. We're looking at early stage clinical assets. I can't say that that's the only thing that we'd look at, maybe something very, very late stage preclinical, but I think our focus is primarily on early stage clinical assets with best in class potential and with small molecules, peptides, things that we have a lot of experience with previously and to sort of leverage our capabilities going forward. Speaker 600:30:21Okay. And then on China, it seemed like you had mentioned that there's clearance there, I guess, in some areas that don't require the bridging study. When would you expect the first revenues to show up from that region? Speaker 200:30:35That's hard to say. I mean, it could it's hard for us to say right now. I mean, we haven't given any guidance on that. We're hoping that 2025 will be a year where there is revenues, although we don't have a lot of control over what's going up what Glory is doing, we're obviously meeting with them on a regular basis. I would imagine that that first sale should occur sometime in 2025. Operator00:31:21A follow-up question from John Van der Mosten of Zacks. Please go ahead. Speaker 600:31:27Great. Thanks for one more. On Gamida Cell, are they is the only other product that they're commercializing the Omnisurge product or do they have something else besides that currently? Speaker 200:31:38Right now, that's what they have. I think they may have plans to bring in some additional products, but right now they have OmniSurg and of course now they have AVEXTA. Speaker 600:31:49Great. All right. Thank you. Operator00:31:53There are no further questions at this time. Before I ask Mr. Phil Serlin to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin 2 hours after the conference. In the U. S, please call 1888-295-2634. Operator00:32:12In Israel, please call 3,9,250,904. Internationally, please call 9723,9,250,9 4. Mr. Serlin, would you like to make your concluding statement? Speaker 200:32:25Yes. Thank you, operator. In closing, we are very pleased to have entered into this licensing agreement with Aramid Gamida Cell, which allows us to return to our drug development roots while simultaneously benefiting from FX's long term commercial potentials in stem cell mobilization, sickle cell disease and other non solid tumor indications. We believe this path forward best positions us to create value for our shareholders while developing novel new therapies for patients with cancer and serious rare diseases. Thank you all very much for your continued interest in BioLineRx. Speaker 200:33:02We look forward to providing our next comprehensive quarterly update in March. Be safe and have a great day. Operator00:33:08Thank you. This concludes the BioLineRx Third Quarter 2024 Conference Call. Thank you for your participation. You may go ahead and disconnect.Read morePowered by